Immunohistochemical analysis of matrix metalloproteinase-9 predicts papillary thyroid carcinoma prognosis

The present study aimed to explore the association between immunohistochemical matrix metalloproteinase-9 (MMP-9) expression and the clinicopathological characteristics of patients with papillary thyroid carcinoma (PTC), and to determine whether it may be used as a diagnostic or prognostic tool for...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2019-02, Vol.17 (2), p.2308-2316
Main Authors: Liu, Xingkai, Su, Chang, Xu, Jing, Zhou, Dan, Yan, He, Li, Wei, Chen, Guihui, Zhang, Nan, Xu, Dahai, Hu, Haixia
Format: Article
Language:English
Subjects:
Age
Angiogenesis
Biomarkers
Body mass index
Cancer metastasis
Cancer therapies
Carcinoma
Care and treatment
Diagnosis
Gene expression
Genetic aspects
Growth factors
Health aspects
Immunohistochemistry
Lymphatic system
Medical prognosis
Medical research
Metastasis
Multivariate analysis
Oncology
Proteases
Thyroid cancer
Thyroid diseases
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study aimed to explore the association between immunohistochemical matrix metalloproteinase-9 (MMP-9) expression and the clinicopathological characteristics of patients with papillary thyroid carcinoma (PTC), and to determine whether it may be used as a diagnostic or prognostic tool for PTC. Immunohistochemical staining of MMP-9 was performed in thyroid tissues obtained from 112 patients with PTC and 42 subjects with benign thyroid nodules (BTNs). The receiver operating characteristic curve was used to evaluate the legitimacy of MMP-9 as a diagnostic tool for PTC, and a predictor for structurally persistent/recurrent disease (SPRD) and disease status. Cox regression was applied to identify the risk factors of disease status and SPRD. The present study revealed that MMP-9 was overexpressed in PTC tissues, compared with in BTN tissues. Furthermore, MMP-9 scores yielded an area under the curve (AUC) of 0.842 (95% CI, 0.776-0.908) for differentially diagnosing PTC from BTN. In addition, the MMP-9 score was greater if patients previously had central lymph node metastasis, lateral lymph node metastasis or an advanced tumor-node-metastasis stage (III+IV). When MMP-9 was employed to predict disease status and SPRD, an AUC of 0.811 (95% CI, 0.706-0.917) and 0.806 (95% CI, 0.620-0.992) was obtained, respectively. A tumor size of >2 cm and an MMP-9 staining score of ≥6 were independent risk factors for predicting disease status, whereas vascular invasion and an MMP-9 staining score of ≥8 were risk factors for predicting SPRD. Furthermore, an MMP-9 staining score of ≥6 and ≥8 indicated shortened disease-free survival and survival without SPRD, respectively. In conclusion, the assessment of MMP-9 expression in thyroid carcinoma samples may represent a potential and supplementary tool for the diagnosis and prognostic prediction of PTC.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2018.9850